Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663169 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00663169 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 6 participants.
The verdict
NCT00663169, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
Interventions
- DRUG dexamethasone
- BIOLOGICAL canakinumab
- OTHER placebo matching canakinumab
- OTHER placebo matching dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663169
The ClinicalTrials.gov registry entry for NCT00663169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00663169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663169 about?
NCT00663169 is a clinical study titled "Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout". This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
What is the current status of trial NCT00663169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00663169?
The interventions under investigation include: dexamethasone (DRUG), canakinumab (BIOLOGICAL), placebo matching canakinumab (OTHER), placebo matching dexamethasone (OTHER).
Who is sponsoring clinical trial NCT00663169?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.